Home / Market News / $APVO

$APVO news and market catalysts

The 12 most recent market catalysts affecting $APVO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

12 catalysts 0 high impact 6 bullish 0 bearish Biotechnology
Nov 17, 2026 Corporate Catalyst Neutral Impact 75
Aptevo Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Progress
Aptevo Therapeutics announced its third-quarter 2026 financial results, reporting a net loss of $6.5 million, an improvement from the prior year. The key highlight is the strong cl…
Nov 13, 2026 Corporate Catalyst Bullish Impact 60
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds
Aptevo Therapeutics executed a warrant inducement, generating $3.0 million in immediate capital by encouraging existing warrant holders to exercise their options at a reduced price…
Nov 9, 2026 Corporate Catalyst Neutral Impact 55
Aptevo Therapeutics Presents New Preclinical Data at SITC 2026
Aptevo Therapeutics presented new preclinical data at the SITC 2026 conference for its next-generation multispecific platform. The data highlighted the potential of three experimen…
Nov 5, 2026 Corporate Catalyst Bullish Impact 65
Aptevo Therapeutics Announces Clinical Milestone for Mipletamig in AML
Aptevo Therapeutics has successfully optimized the priming-dose regimen for its lead candidate, mipletamig, significantly reducing infusion-related reactions in AML patients. This …
Oct 26, 2026 Corporate Catalyst Bullish Impact 65
Aptevo Therapeutics Reports Clinical Milestone for Mipletamig Combination Therapy in AML Patients
Aptevo Therapeutics reported a clinical milestone where 10 AML patients treated with their mipletamig combination therapy successfully advanced to allogeneic stem cell transplant. …
Sep 24, 2026 Corporate Catalyst Neutral Impact 55
Aptevo Expects To Enter Investigational New Drug-Enabling Studies For Its Lead Candidate APVO451 In H1 2027
Aptevo Therapeutics is providing an update on its next-generation trispecific immuno-oncology programs, specifically stating that its lead candidate, APVO451, is expected to enter …
Sep 3, 2026 Corporate Catalyst Bullish Impact 75
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
Aptevo Therapeutics reported a 93% clinical benefit rate for its drug mipletamig in a triplet therapy for frontline acute myeloid leukemia (AML) patients with TP53 mutations. This …
Sep 3, 2026 Corporate Catalyst Bullish Impact 75
Aptevo Reports 93% Clinical Benefit Rate With Mipletamig Triplet in Evaluable Frontline Acute Myeloid Keukemia Patients With TP53 Mutations
Aptevo Therapeutics reported a 93% clinical benefit rate for its Mipletamig triplet in frontline acute myeloid leukemia patients with TP53 mutations. This is a significant positive…
Sep 2, 2026 Corporate Catalyst Neutral Impact 65
Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS".
Aptevo Therapeutics has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering 'TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED …
Aug 24, 2026 Corporate Catalyst Neutral Impact 55
Watching Aptevo Therapeutics; Zacks Small-Cap Research Gives Stock $30 Price Valuation
The headline signals a positive development for Aptevo Therapeutics (APVO) due to a $30 price valuation from Zacks Small-Cap Research. This could lead to increased investor interes…
Aug 13, 2026 Corporate Catalyst Neutral Impact 65
Aptevo Therapeutics Closes Warrant Inducement Transaction, Issuing New Warrants For 1.27M Shares At $4.03 Per Share; Sells 861,708 Shares In $4.03 PIPE
Aptevo Therapeutics has closed two financing activities: a warrant inducement transaction and a private placement (PIPE). In the warrant inducement, existing warrant holders exerci…
Jul 27, 2026 Corporate Catalyst Bullish Impact 65
Reported Earlier: Aptevo Therapeutics Announces A New Solid Strategy Designed To Fight Cancer On Multiple Fronts; Files A Patent Application Covering A Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone Designed To Strengthen Aptevo's Oncology Pipeline
Aptevo Therapeutics has filed a patent application for a novel Nectin-4 x PD-L1 dual-targeting backbone, which is central to its new solid tumor strategy. This move is significant …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.